Skip to main content

Advertisement

Table 1 Patient demographics and disease characteristics at baseline

From: Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

Parameter Value (N = 50)
Mean age (range), years 69.3 (44–91)
Men,% 58
Race/ethnicity,%  
  White 86.0
  Black/African American 8.0
  Asian 2.0
  Pacific Islander 2.0
  Other 2.0
Mean body mass index (SD), kg/m2 25.0 (4.37)
Myelofibrosis subtype,%  
  PMF 62.0
  PPV-MF 30.0
  PET-MF 8.0
DIPSS risk category,%  
  High 20.0
  Intermediate-2 62.0
  Intermediate-1 18.0
ECOG status,%  
  0 12.0
  1 74.0
  2 12.0
  Missing 2.0
History of transfusion in 12 weeks before baseline,% 40.0
Previous HU use,% 44.0
Mean platelet count (SD), × 109/L 72.1 (21.9)
Mean hemoglobin (SD), g/L 97.3 (15.7)
Mean WBC (SD), × 109/L 19.6 (20.2)
Mean TSS (SD) 19.4 (11.8)
Mean spleen length (SD), cm 13.4 (7.2)
Mean spleen volume (SD), cm3 2387.3 (1527.3)
  1. Samples will be analyzed for JAK2V617F status at the end of study.
  2. DIPSS, Dynamic International Prognostic Scoring System; ECOG, Eastern Cooperative Oncology Group; HU, hydroxyurea; JAK, Janus kinase; PET-MF, post-essential thrombocythemia myelofibrosis; PMF, primary myelofibrosis; PPV-MF, post-polycythemia vera myelofibrosis; SD, standard deviation; TSS, Total Symptom Score; WBC, white blood cell.